TY - JOUR
T1 - Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study
AU - Abutbul, Avraham
AU - Mumblat, Helena
AU - Porat, Yaara
AU - Friedman, Nehemya
AU - Atari, Nofar
AU - Sharabi, Shirley
AU - Nama, Ahmad
AU - Mugahed, Waseem
AU - Kessler, Asa
AU - Kolben, Yotam
AU - Shamir, Reuben Ruby
AU - Manzur, Doron
AU - Farber, Ori
AU - Bosch, Liora
AU - Lavy-Shahaf, Gitit
AU - Dor-On, Eyal
AU - Haber, Adi
AU - Giladi, Moshe
AU - Weinberg, Uri
AU - Palti, Yoram
AU - Mardor, Yael
AU - Mandelboim, Michal
N1 - Publisher Copyright:
Copyright © 2023 Abutbul, Mumblat, Porat, Friedman, Atari, Sharabi, Nama, Mugahed, Kessler, Kolben, Shamir, Manzur, Farber, Bosch, Lavy-Shahaf, Dor-On, Haber, Giladi, Weinberg, Palti, Mardor and Mandelboim.
PY - 2023
Y1 - 2023
N2 - Coronaviruses are the causative agents of several recent outbreaks, including the COVID-19 pandemic. One therapeutic approach is blocking viral binding to the host receptor. As binding largely depends on electrostatic interactions, we hypothesized possible inhibition of viral infection through application of electric fields, and tested the effectiveness of Tumor Treating Fields (TTFields), a clinically approved cancer treatment based on delivery of electric fields. In preclinical models, TTFields were found to inhibit coronavirus infection and replication, leading to lower viral secretion and higher cell survival, and to formation of progeny virions with lower infectivity, overall demonstrating antiviral activity. In a pilot clinical study (NCT04953234), TTFields therapy was safe for patients with severe COVID-19, also demonstrating preliminary effectiveness data, that correlated with higher device usage.
AB - Coronaviruses are the causative agents of several recent outbreaks, including the COVID-19 pandemic. One therapeutic approach is blocking viral binding to the host receptor. As binding largely depends on electrostatic interactions, we hypothesized possible inhibition of viral infection through application of electric fields, and tested the effectiveness of Tumor Treating Fields (TTFields), a clinically approved cancer treatment based on delivery of electric fields. In preclinical models, TTFields were found to inhibit coronavirus infection and replication, leading to lower viral secretion and higher cell survival, and to formation of progeny virions with lower infectivity, overall demonstrating antiviral activity. In a pilot clinical study (NCT04953234), TTFields therapy was safe for patients with severe COVID-19, also demonstrating preliminary effectiveness data, that correlated with higher device usage.
KW - COVID-19
KW - Tumor Treating Fields (TTFields)
KW - antiviral activity
KW - clinical safety
KW - coronavirus
UR - http://www.scopus.com/inward/record.url?scp=85179343410&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2023.1296558
DO - 10.3389/fmicb.2023.1296558
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38094629
AN - SCOPUS:85179343410
SN - 1664-302X
VL - 14
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 1296558
ER -
